Biden administration has also taken over distributing the therapeutics to help avoid shortages and to ensure equitable distribution
Baricitinib Does Not Cut COVID-19 Progression in Hospitalized Adults
But placebo-controlled trial shows lower all-cause mortality at 28 days and 60 days in patients receiving baricitinib plus standard of care
Stop Use of Ivermectin for COVID-19: AMA, Pharmacist Groups
No form of ivermectin has been approved to treat or prevent COVID-19
Monoclonal Antibody Therapy May Cut COVID-19 Hospitalizations
Lower hospitalization rates seen at 14, 21, 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab
Prescriptions Rise for Veterinary Drug for COVID-19 Patients
Increase in demand for ivermectin has been accompanied by a fivefold increase in calls to poison control centers
Stop Using Ivermectin Veterinary Drug to Treat COVID-19, FDA Urges
No form of ivermectin has been approved to treat or prevent COVID-19, the agency emphasized
Dexamethasone Underused for Adults Hospitalized With COVID-19
Dexamethasone and remdesivir use have gradually increased during the pandemic; hydroxychloroquine use peaked in March 2020
AAP: Consider Palivizumab for Atypical Interseasonal RSV
AAP strongly supports consideration of palivizumab for patients who would be candidates per current eligibility recommendations
Antibody Combo Prevents Infection From SARS-CoV-2 Exposure
Single dose of REGEN-COV reduces symptomatic, asymptomatic infection risk in household contacts of infected persons for 28-day period
Papers on COVID-19 in Psoriasis, Psoriatic Arthritis Carry Risk for Bias
Risk for bias high in papers relating to patients with psoriasis and psoriatic arthritis receiving biologic therapies